Biotech4 hours ago
AbbVie’s TEMPLE Study Shows Atogepant Outperforms Topiramate in Migraine Prevention
AbbVie will present Phase III TEMPLE study results at the 2025 International Headache Congress, showing atogepant’s superior tolerability and efficacy over topiramate for migraine prevention. Atogepant...